# PD-1/ PD-L1 Bispecific Antibody IBI318 Combined with Lenvatinib in Advanced Non-Small Cell Lung Cancer with Acquired Resistance to Immune Checkpoint Inhibitors: A Phase II Trial

Note: 
1) All necessary analytical data have been deposited in the GSA database and uploaded as source data with the manuscript.
2) For any questions, please contact: ruanzh5167@outlook.com
